Partner and Chairman, MD, DPhil

#fhtogglels/Read Full Bio/Close/ib

Fred Cohen is a Founder and member of the Investment Committee of Monograph, which he co-founded in 2021. Prior to Monograph, he was Co-Founder and Senior Managing Director of Vida Ventures, and Managing Partner at TPG Biotechnology, where he initiated TPG’s venture efforts in biotechnology and life sciences in 2001.

Earlier, Fred was a Professor at UCSF, where he served as Chief of the Division of Endocrinology and Metabolism and led research in prionbiology, drug design, bioinformatics, and heteropolymer chemistry. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, and a fellow of the American College of Physicians. He has received several awards, including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize, and the Searle Scholars Award. Fred graduated magna cum laude from Yale University in 1978, received his D.Phil. from Oxford University as a Rhodes Scholar in 1980, earned his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and completed his internal medicine and endocrinology training at UCSF.

LinkedIn

Partner, MBA, MA

#fhtogglels/Read Full Bio/Close/ib

Charles Conn is a Partner and Founder of Monograph. Before co-founding Monograph, Charles was CEO of Oxford Sciences Innovation, a deep science venture firm with approximately £600 million of assets under management formed in partnership with Oxford University. Charles is a technology entrepreneur and former public company CEO (of companies including Ticketmaster, Citysearch and Match.com).

He serves as chair of the board of Patagonia and was previously CEO of the Rhodes Trust in Oxford. Previously he was senior advisor to the Gordon & Betty Moore Foundation in San Francisco.

He began his career at McKinsey & Company, where he was a Partner. He is a best-selling author on problem solving, and is a member of The Nature Conservancy’s European Council for Global Conservation. Charles is a graduate of Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.

LinkedIn

Partner, DPhil, BS

#fhtogglels/Read Full Bio/Close/ib

Tim Funnell is a Partner and co-Founder at Monograph. Prior to Monograph, Tim was co-founder and Vice President of Operations for MiroBio. Tim has been an investor in the biotechnology and related life sciences industries and company-builder at Syncona, Third Rock Ventures and Oxford Sciences, gaining experience across therapeutic modalities and geographies. He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist with an undergraduate degree from University of Cambridge and DPhil from the University of Oxford.

Linkedin

Partner and COO, JD, MBA, LLM

#fhtogglels/Read Full Bio/Close/ib

Mike LaGatta is a Partner and Chief Operating Officer at Monograph. Prior to joining Monograph, Mike served as the General Counsel of TPG Holdings and Chief Tax Officer of TPG. Mike brings over 20 years of investment management and transactional experience.

LinkedIn

Partner, MSc, MD, BS

#fhtogglels/Read Full Bio/Close/ib

Travis Murdoch is a Partner and co-Founder at Monograph and CEO of portfolio company Human Immunology Biosciences (“Hi-Bio”), a precision immunology company. Prior to Monograph, Travis was a life sciences investor with Softbank Vision Fund, where he oversaw investments in Relay Therapeutics (NASDAQ: RLAY), Vividion Therapeutics (Acqby: BAYRY), Seer (NASDAQ: SEER), VIR (NASDAQ: VIR), Zymergen(NASDAQ: ZY), ElevateBio, Encoded Therapeutics, Insitro, Karius, and Collective Health.

He was previously a Principal at Third Rock Ventures, and a consultant at McKinsey & Company. Travis is a gastroenterologist who worked with Northern communities in Canada. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.

LinkedIn

Principal (Portfolio), BSc

#fhtogglels/Read Full Bio/Close/ib

Freddie Dear is a Portfolio Principal at Monograph and currently deployed in portfolio company Ascend Advanced Therapies as VP, Corporate Development. Prior to Ascend and Monograph, he was an Investment Partner at Syncona, where he was involved in a number of investments including Quell Therapeutics and Forcefield Therapeutics, where he held board observer roles. Prior to Syncona, he was a member of the investment team at the Wellcome Trust. Freddie holds an BSc in Biochemistry from the University of Edinburgh.

LinkedIn

Principal (Portfolio), PhD, BS

#fhtogglels/Read Full Bio/Close/ib

Jaideep Dudani is a Portfolio Principal at Monograph and leads Portfolio Development at Monograph’s portfolio company, Hi-Bio. He was most recently at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development.

Before that, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (which held its initial public offering on the NASDAQ Global Select Market in 2018), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (which held its initial public offering on the NASDAQ Global Select Market in 2019), and Pionyr Immunotherapeutics (which was acquired by Gilead Sciences, Inc. in 2020).

He completed his PhD at MIT in Biological Engineering, and holds a BS in Bioengineering from UCLA.

LinkedIn

Associate, PhD, MSc, BSc

#fhtogglels/Read Full Bio/Close/ib

Melisa joined Monograph Capital from L.E.K. Consulting, where she was an Engagement Manager in the Healthcare and Life Sciences practice, working with biopharma, contract services organisations, diagnostics and research tools providers and investors. She was also a fellow with the World Economic Forum’s Healthcare Industries Platform. She completed her PhD in cancer biology focusing on DNA repair at the Francis Crick Institute, with multiple publications. She also holds a BSc in Biochemistry and MSc in Immunology, from Imperial College London.

LinkedIn

Head of Finance, IMC, ACA, MBiochem

#fhtogglels/Read Full Bio/Close/ib

Having qualified as an ICAEW Chartered Accountant and auditor from PwC’s Insurance and Investment Management practice, Nishat has worked in the finance teams of several not-for-profit organisations. Her most recent role was at the Coalition for Epidemic Preparedness Innovations. Nishat has an Investment Management Certificate from CFA UK and earned a Masters in Biochemistry at Oxford University.

LinkedIn

EA + SF Office Manager, BBA

#fhtogglels/Read Full Bio/Close/ib

Kristina is an EA and Office Manager at Monograph's San Francisco office. She has extensive experience supporting C-Suite executives in the biotech industry, including roles as executive assistant to the CEO at Walking Fish Therapeutics and senior executive assistant to the General Counsel at Frontier Medicines. Previously, she was the operations manager and executive assistant to the CEO at CODA Biotherapeutics, and supported senior executives at FivePrime Therapeutics (acquired by Amgen) and FibroGen. Kristina also has experience in commercial real estate and private equity and holds a BBA from Mount Mercy University.

Linkedin

Head of Capital Formation, BA

#fhtogglels/Read Full Bio/Close/ib

Jennifer Shah serves as the Head of Capital Formation, where she leads strategic initiatives for fundraising and investor relations. Prior to Monograph, Jennifer was the Director, Head of Product Management, Fundraising & Investor Relations at Silver Lake, where she managed capital raising efforts for their flagship fund. Before Silver Lake, she was a Director of Capital Raising at SoftBank Investment Advisers. Jennifer also worked at TPG as a Principal in the Funding Group, where she focused on their TPG Asia funds. Jennifer holds a BA in Anthropology and International Studies from Trinity College.

LinkedIn

Chief of Staff & EA, BA

#fhtogglels/Read Full Bio/Close/ib

Brandi is Chief of Staff and EA to Fred Cohen. Previously, Brandi supported several leaders at TPG, including Co-CEO Jon Winkelried, Senior Advisors Dr Fred Cohen, Edward Mower Norton Jr, and the Honorable William K. Reilly. Brandi began her career as an assistant working aboard M.Y. Silver Lining. She continued her career at the Santa Fe Film Festival, the Doha Film Institute in Qatar, and the 34th America’s Cup in San Francisco, before moving into private equity and venture capital. Brand holds a BA in Communications from the University of Louisville.

LinkedIn

Executive Assistant

#fhtogglels/Read Full Bio/Close/ib

Jo has extensive experience supporting high net worth individuals within private equity, real estate, property and asset management. Prior to joining Monograph, Jo was EA to the Chairman & CEO at James Hambro & Partners. Previously, Jo worked at, Pacific Investments Plc and for a number of boutique property businesses.

Principal, DPhil, BS

#fhtogglels/Read Full Bio/Close/ib

Bonnie van Wilgenburg is a Principal at Monograph. Prior to joining Monograph, Bonnie worked for four years at a leading European venture capital firm, Forbion, where her activities included sourcing, evaluation, deal execution and portfolio management of life science companies. She was a board observer at Inflazome, which was sold to Roche in 2020 for US$450 million plus milestone payments. Before that she worked for a decade as an academic scientist in the fields of immunology, virology and stem cells at Oxford University and the University of Melbourne. She earned her DPhil at Oxford.

LinkedIn

Associate, MPH, BM BCh, MA

#fhtogglels/Read Full Bio/Close/ib

Charlie joined Monograph Capital from Bain and Company, where he worked within the private equity advisory team, with a focus on the healthcare sector. He completed his medical training at Cambridge University and Oxford University prior to practicing at the Royal Free NHS Foundation Trust. Charlie also completed a Master of Public Health at Harvard University as a Fulbright Scholar, and contributed to research as a visiting scientist at the Harvard T.H. Chan School of Public Health.

LinkedIn